Related Experiment Video

Updated: May 12, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central

Christian Boch1, Jens Kollmeier, Andreas Roth

  • 1Klinik für Pneumologie, Lungenklinik Heckeshorn, HELIOS Klinikum Emil von Behring, Berlin, Berlin, Germany.

BMJ Open
|April 6, 2013
PubMed
Abstract

Insights

This study found lower frequencies of epidermal growth factor receptor (EGFR) and KRAS mutations in an unselected non-small cell lung carcinoma (NSCLC) patient cohort. These findings suggest clinical trials may overestimate mutation rates due to selection bias.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Genetics

Background:

  • Molecular analysis of EGFR and KRAS mutations is crucial for targeted therapies in non-small cell lung carcinoma (NSCLC).
  • Existing data on mutation frequencies are often derived from pre-selected patient populations in clinical trials.
  • Screening an 'allcomers' cohort provides a more accurate representation of mutation prevalence in routine diagnostics.

Purpose of the Study:

  • To determine the frequencies of EGFR and KRAS mutations in an unselected cohort of newly diagnosed NSCLC patients.
  • To compare mutation frequencies in an unselected population with those reported in clinical trials.
  • To identify potential selection biases in current NSCLC trial data.

Main Methods:

  • A cohort study was conducted at a tertiary care hospital over 15 months.
  • 552 eligible NSCLC cases were analyzed for mutations in EGFR (exons 18, 19, 21) and KRAS (codons 12, 13).
  • Patient demographics, histology, and smoking status were recorded.

Main Results:

  • EGFR mutations were found in 4.9% of patients, with common alterations in codons 19 and 21.
  • KRAS mutations were present in 15% of cases, predominantly in codon 12.
  • Adenocarcinoma histology showed significantly higher frequencies for both EGFR and KRAS mutations compared to non-adenocarcinoma types.

Conclusions:

  • The frequency of EGFR and KRAS mutations in this unselected Caucasian NSCLC cohort is lower than previously reported.
  • Clinical trials may overestimate EGFR and KRAS mutation frequencies in NSCLC due to inherent selection biases.
  • These findings highlight the importance of analyzing unselected 'allcomers' populations for accurate molecular profiling in NSCLC.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...